bpc 157 human research BPC‑157 Peptide Regeneration or Risk? A Narrative
Description
While the Phase 2 trial did not specifically stratify outcomes by baseline eGFR, GLP-1 receptor agonists as a class have demonstrated renoprotective effects in at-risk populations
In a system already running low on dopaminergic tone from GLP-1 protocols, this stabilization may anchor the system further in a suppressed state rather than correcting it
This can help people lose weight and improve their blood sugar levels
However, I am looking into other alternatives that are cheaper
